Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis.

摘要: Institutionalized adults with severe developmental disabilities have a high rate of minimal trauma and appendicular fracture. There is little information about osteoporosis treatment in this population. In efficacy safety study, men women received 20 mcg teriparatide subcutaneously daily for 18–24 months. Markers bone formation [procollagen type 1 intact N-terminal propeptide (P1NP)] resorption [C-telopeptide (CTx)] were measured at three-month intervals. Serum calcium was two-week intervals 12 weeks thereafter Twenty-seven individuals least one injection. The incidence hypercalcemia 11.1% but persistent led to medication discontinuation only participant. Biomarkers increased rapidly, doubling by three months. At 12 months, P1NP CTx remained elevated from baseline; had risen 66.95 ± 83.71 μg/l (mean ± SD) 142.42 ± 113.85 μg/l (P = 0.05), 0.377 ± 0.253 1.016 ± 1.048 ng/ml (P = 0.01). majority participants an increase over 10 μg/l. conclusion, safe effective developmentally disabled institutionalized adults. Serial measurements are warranted, particularly during the first months therapy.